Loading company…
Metabolic Solutions Development develops drugs for metabolic diseases linked to mitochondrial dysfunction.
Founded in 2006 and based in Michigan, US, Metabolic Solutions Development develops therapeutics for metabolic diseases linked to age-related mitochondrial dysfunction, including insulin resistance and type 2 diabetes. Its mTOT modulators include MSDC-0160 and MSDC-0602. In January 2019, it raised USD 0.20 million in venture debt financing.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in